Retrospective Analysis of Risk Factors for Related Complications of Chemical Ablation on Hypertrophic Obstructive Cardiomyopathy

Overview

Journal Arq Bras Cardiol

Specialty Cardiology & Vascular Diseases

Date 2019 Apr 4

PMID 30942295

Citations 2

Authors

Cheng-Yang Li

Yun-Qi Shi

Affiliations

Soon will be listed here.

Abstract

Background: The analysis of risk factors for predicting related complications has not been reported to date.

Objective: This study aims to investigate the risk factors of related complications of percutaneous transluminal septal myocardial ablation (PTSMA) for hypertrophic obstructive cardiomyopathy (HOCM) retrospectively.

Method: Clinical data, and one-year follow-up results of patients with HOCM, who underwent PTSMA between January 2000 and July 2013 in the Department of Cardiology, Liaoning Province People's Hospital, Liaoning Province, China, were retrospectively analyzed to determine risk factors for operative complications with multiple logistic regression analysis. All p values are two-sided, with values of p < 0.05 being considered statistically significant.

Results: Among 319 patients with HOCM, PTSMA was performed in 224 patients (120 males and 104 females, mean age was 48.20 ± 14.34 years old). The incidence of PTSMA procedure-related complications was 36.23% (66/224), which included three cardiac deaths, two cardiac shocks, one ST-segment elevated myocardial infarction, two ventricular fibrillations, 20 third-degree atrioventricular (AV) blocks (four patients were implanted with a permanent pacemaker (PPM)), 32 complete right bundle branch blocks, two complete left bundle branch blocks, and four puncture-related complications. After multivariate logistic regression analysis, it was found that age, gender, coronary artery diseases, diabetes, heart rate, cardiac function on admission, the number of septal ablations, and the volume of alcohol were not independent risk factors correlated to the whole complications, except for hypertension (OR: 4.856; 95% CI: 1.732-13.609). Early experience appears to be associated with the occurrence of complications.

Conclusion: Hypertension was an independent risk factor for PTSMA procedure-related complications. It might be much safer and more efficient if PTSMA procedures are restricted to experienced centers, according to the analysis results for the learning curve.

Citing Articles

Alcohol-induced right bundle branch block is associated with a benign outcome in HOCM after alcohol septum ablation (ASA).

Lawin D, Lawrenz T, Radke K, Wolff A, Stellbrink C Clin Res Cardiol. 2021; 111(2):175-185.

PMID: 33772362 DOI: 10.1007/s00392-021-01847-6.

Septal Ablation in Obstructive Hypertrophic Cardiomyopathy (oHCM).

Almeida D Arq Bras Cardiol. 2019; 112(4):439-440.

PMID: 30994723 PMC: 6459442. DOI: 10.5935/abc.20190066.

References

Gomes O, Coelho A, Osterne E, Abrantes R . Coronary morphology and conduction system disturbance induced by therapeutic embolization of the coronary septal artery. Heart Surg Forum. 2010; 13(1):E45-8. DOI: 10.1532/HSF98.20091133. View

Moon J, Cho I, Shim C, Ha J, Jang Y, Chung N . Abnormal myocardial capillary density in apical hypertrophic cardiomyopathy can be assessed by myocardial contrast echocardiography. Circ J. 2010; 74(10):2166-72. DOI: 10.1253/circj.cj-10-0241. View

Kimura A . Contribution of genetic factors to the pathogenesis of dilated cardiomyopathy: the cause of dilated cardiomyopathy: genetic or acquired? (genetic-side). Circ J. 2011; 75(7):1756-65. DOI: 10.1253/circj.cj-11-0368. View

Qiao S, Yuan J . [How to improve the safety of percutaneous transluminal septal myocardial ablation]. Zhonghua Xin Xue Guan Bing Za Zhi. 2011; 39(3):193-5. View

El-Jack S, Nasif M, Blake J, Dixon S, Grines C, ONeill W . Predictors of complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy and the timing of pacemaker implantation. J Interv Cardiol. 2007; 20(1):73-6. DOI: 10.1111/j.1540-8183.2007.00220.x. View

Parry D, Raskin R, Poynter J, Ribero I, Bajona P, Rakowski H . Short and medium term outcomes of surgery for patients with hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2015; 99(4):1213-9. DOI: 10.1016/j.athoracsur.2014.11.020. View

Nemes A, Balazs E, Soliman O, Sepp R, Csanady M, Forster T . Long-term prognostic value of coronary flow velocity reserve in patients with hypertrophic cardiomyopathy: 9-year follow-up results from SZEGED study. Heart Vessels. 2009; 24(5):352-6. DOI: 10.1007/s00380-008-1131-0. View

van der Lee C, Scholzel B, Ten Berg J, Geleijnse M, Idzerda H, van Domburg R . Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation. Am J Cardiol. 2008; 101(9):1315-20. DOI: 10.1016/j.amjcard.2008.01.003. View

Faber L, Welge D, Fassbender D, Schmidt H, Horstkotte D, Seggewiss H . Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances. Int J Cardiol. 2006; 119(2):163-7. DOI: 10.1016/j.ijcard.2006.07.179. View

10.

Gersh B, Maron B, Bonow R, Dearani J, Fifer M, Link M . 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 124(24):2761-96. DOI: 10.1161/CIR.0b013e318223e230. View

11.

Jensen M, Almaas V, Jacobsson L, Hansen P, Havndrup O, Aakhus S . Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: a Scandinavian multicenter study. Circ Cardiovasc Interv. 2011; 4(3):256-65. DOI: 10.1161/CIRCINTERVENTIONS.110.959718. View

12.

Caselli S, Maron M, Urbano-Moral J, Pandian N, Maron B, Pelliccia A . Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2014; 114(9):1383-9. DOI: 10.1016/j.amjcard.2014.07.070. View

13.

Rigopoulos A, Seggewiss H . A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. Circ J. 2010; 75(1):28-37. DOI: 10.1253/circj.cj-10-0962. View

14.

Veselka J, Zemanek D, Tomasov P, Duchonova R, Linhartova K . Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective. Heart Vessels. 2009; 24(1):27-31. DOI: 10.1007/s00380-008-1083-4. View

15.

Madsen L, Lund T, Grieg Z, Nygaard S, Holmvang L, Jurlander B . Cardiac troponin I degradation in serum of patients with hypertrophic obstructive cardiomyopathy undergoing percutaneous septal ablation. Cardiology. 2009; 114(3):167-73. DOI: 10.1159/000226596. View

16.

Efthimiadis G, Pitsis A, Pagourelias E, Kamperidis V, Kelpis T, Meditskou S . Surgical septal myectomy for hypertrophic cardiomyopathy in Greece: a single-center initial experience. Hellenic J Cardiol. 2014; 55(2):132-8. View

17.

Chikkabasavaiah N, Puttegowda B, Panneerselvam A, Ananthakrishna R, Kapanigowda A, Basavappa R . Remote infarction following percutaneous transluminal septal myocardial ablation: a report of two cases. Cardiovasc Interv Ther. 2013; 26(2):142-6. DOI: 10.1007/s12928-010-0038-8. View

18.

Jensen M, Havndrup O, Hassager C, Helqvist S, Kelbaek H, Jorgensen E . Survival and sudden cardiac death after septal ablation for hypertrophic obstructive cardiomyopathy. Scand Cardiovasc J. 2011; 45(3):153-60. DOI: 10.3109/14017431.2011.565793. View

19.

Rosella L, Lebenbaum M, Fitzpatrick T, Zuk A, Booth G . Prevalence of Prediabetes and Undiagnosed Diabetes in Canada (2007-2011) According to Fasting Plasma Glucose and HbA1c Screening Criteria. Diabetes Care. 2015; 38(7):1299-305. DOI: 10.2337/dc14-2474. View

20.

Gersh B, Maron B, Bonow R, Dearani J, Fifer M, Link M . 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the.... J Am Coll Cardiol. 2011; 58(25):e212-60. DOI: 10.1016/j.jacc.2011.06.011. View